

Kidney Cancer and Renal Cell Carcinoma Drugs Market - 2022

<https://marketpublishers.com/r/KFED61EF1DC3EN.html>

Date: December 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: KFED61EF1DC3EN

Abstracts

The Kidney Cancer and Renal Cell Carcinoma Drugs Market was valued at USD 5.6 billion in 2022 and is anticipated to reach by , at a CAGR of 0.063 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Kidney Cancer and Renal Cell Carcinoma Drugs Market.

This report delivers a comprehensive overview of the Kidney Cancer and Renal Cell Carcinoma Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma Drugs Market. The Kidney Cancer and Renal Cell Carcinoma Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Kidney Cancer and Renal Cell Carcinoma Drugs Market Scope:

By Product

Bevacizumab

Everolimus

Cabozantinib

Axitinib

Sorafenib

Temsirolimus

Sunitinib

Pazopanib

By End-users

Hospitals

Ambulatory Surgical Centers

Specialty Centers

Others

By End-user

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Roche Inc

GlaxoSmithKline Plc.

Active Biotech Ab

Heidelberg Pharma AG, Inc.

Bristol-Myers Squibb

Eisai

Exelixis

Novartis AG

Amgen

Bayer AG

Major Highlights

This report delivers a comprehensive overview of the Kidney Cancer and Renal Cell Carcinoma Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma Drugs Market. The Kidney Cancer and Renal Cell Carcinoma Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Product
- 3.2. Snippet by End-users
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Growing incidences of kidney and RCC cases
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with These Drugs
 - 4.1.3. Opportunity
 - 4.1.3.1. Research and development
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19
 - 6.1.2. Scenario During COVID-19

- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY PRODUCT

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
 - 9.1.2. Market Attractiveness Index, By Product
- 9.2. Bevacizumab*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Everolimus
- 9.4. Cabozantinib
- 9.5. Axitinib
- 9.6. Sorafenib
- 9.7. Temsirolimus
- 9.8. Sunitinib
- 9.9. Pazopanib

10. BY END-USERS

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
 - 10.1.2. Market Attractiveness Index, By End-users
- 10.2. Hospitals*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Ambulatory Surgical Centers
- 10.4. Specialty Centers
- 10.5. Others

11. BY END-USER

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

11.1.2. Market Attractiveness Index, By End-user

11.2. Hospital Pharmacies*

11.2.1. Introduction

11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

11.3. Retail Pharmacies

11.4. Online Pharmacies

12. BY REGION

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

12.1.2. Market Attractiveness Index, By Region

12.2. North America

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.2.6.1. The U.S.

12.2.6.2. Canada

12.2.6.3. Mexico

12.3. Europe

12.3.1. Introduction

12.3.2. Key Region-Specific Dynamics

12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.3.6.1. Germany

12.3.6.2. The U.K.

12.3.6.3. France

12.3.6.4. Italy

12.3.6.5. Spain

12.3.6.6. Rest of Europe

12.4. South America

12.4.1. Introduction

12.4.2. Key Region-Specific Dynamics

12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.4.6.1. Brazil

12.4.6.2. Argentina

12.4.6.3. Rest of South America

12.5. Asia-Pacific

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.5.6.1. China

12.5.6.2. India

12.5.6.3. Japan

12.5.6.4. Australia

12.5.6.5. Rest of Asia-Pacific

12.6. Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1. Competitive Scenario

13.2. Product Benchmarking

13.3. Company Share Analysis

13.4. Key Developments and Strategies

14. COMPANY PROFILES

14.1. Roche Inc*

- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
- 14.2. GlaxoSmithKline Plc.
- 14.3. Active Biotech Ab
- 14.4. Heidelberg Pharma AG, Inc.
- 14.5. Bristol-Myers Squibb
- 14.6. Eisai
- 14.7. Exelixis
- 14.8. Novartis AG
- 14.9. Amgen
- 14.10. Bayer AG (*LIST NOT EXHAUSTIVE)

15. APPENDIX

- 15.1. About Us and Services
- 15.2. Contact Us

I would like to order

Product name: Kidney Cancer and Renal Cell Carcinoma Drugs Market - 2022

Product link: <https://marketpublishers.com/r/KFED61EF1DC3EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/KFED61EF1DC3EN.html>